Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 105

1.

Antibody-independent B cell effector functions in relapsing remitting multiple sclerosis: clues to increased inflammatory and reduced regulatory B cell capacity.

Ireland SJ, Blazek M, Harp CT, Greenberg B, Frohman EM, Davis LS, Monson NL.

Autoimmunity. 2012 Aug;45(5):400-14. doi: 10.3109/08916934.2012.665529. Epub 2012 Apr 18. Review.

PMID:
22432732
2.

Secretory products of multiple sclerosis B cells are cytotoxic to oligodendroglia in vitro.

Lisak RP, Benjamins JA, Nedelkoska L, Barger JL, Ragheb S, Fan B, Ouamara N, Johnson TA, Rajasekharan S, Bar-Or A.

J Neuroimmunol. 2012 May 15;246(1-2):85-95. doi: 10.1016/j.jneuroim.2012.02.015. Epub 2012 Mar 28.

PMID:
22458983
3.

Memory and naïve B-cell subsets in patients with multiple sclerosis.

Niino M, Hirotani M, Miyazaki Y, Sasaki H.

Neurosci Lett. 2009 Oct 16;464(1):74-8. doi: 10.1016/j.neulet.2009.08.010. Epub 2009 Aug 8.

PMID:
19666086
4.

B cells as a therapeutic target for IFN-β in relapsing-remitting multiple sclerosis.

Ramgolam VS, Sha Y, Marcus KL, Choudhary N, Troiani L, Chopra M, Markovic-Plese S.

J Immunol. 2011 Apr 1;186(7):4518-26. doi: 10.4049/jimmunol.1000271. Epub 2011 Mar 2.

5.

The B1-cell subpopulation is diminished in patients with relapsing-remitting multiple sclerosis.

Tørring C, Petersen CC, Bjerg L, Kofod-Olsen E, Petersen T, Höllsberg P.

J Neuroimmunol. 2013 Sep 15;262(1-2):92-9. doi: 10.1016/j.jneuroim.2013.06.002. Epub 2013 Jul 12.

PMID:
23856341
6.

Fingolimod therapy modulates circulating B cell composition, increases B regulatory subsets and production of IL-10 and TGFβ in patients with Multiple Sclerosis.

Blumenfeld S, Staun-Ram E, Miller A.

J Autoimmun. 2016 Jun;70:40-51. doi: 10.1016/j.jaut.2016.03.012. Epub 2016 Apr 4.

PMID:
27055778
7.

Reduction in IL-10 producing B cells (Breg) in multiple sclerosis is accompanied by a reduced naïve/memory Breg ratio during a relapse but not in remission.

Knippenberg S, Peelen E, Smolders J, Thewissen M, Menheere P, Cohen Tervaert JW, Hupperts R, Damoiseaux J.

J Neuroimmunol. 2011 Oct 28;239(1-2):80-6. doi: 10.1016/j.jneuroim.2011.08.019. Epub 2011 Sep 21.

PMID:
21940055
8.

Memory B cells from a subset of treatment-naïve relapsing-remitting multiple sclerosis patients elicit CD4(+) T-cell proliferation and IFN-γ production in response to myelin basic protein and myelin oligodendrocyte glycoprotein.

Harp CT, Ireland S, Davis LS, Remington G, Cassidy B, Cravens PD, Stuve O, Lovett-Racke AE, Eagar TN, Greenberg BM, Racke MK, Cowell LG, Karandikar NJ, Frohman EM, Monson NL.

Eur J Immunol. 2010 Oct;40(10):2942-56. doi: 10.1002/eji.201040516.

9.

Imbalance in T-cell and cytokine profiles in patients with relapsing-remitting multiple sclerosis.

Mikulkova Z, Praksova P, Stourac P, Bednarik J, Michalek J.

J Neurol Sci. 2011 Jan 15;300(1-2):135-41. doi: 10.1016/j.jns.2010.08.053.

PMID:
20884014
10.

Distinct effector cytokine profiles of memory and naive human B cell subsets and implication in multiple sclerosis.

Duddy M, Niino M, Adatia F, Hebert S, Freedman M, Atkins H, Kim HJ, Bar-Or A.

J Immunol. 2007 May 15;178(10):6092-9.

11.

Memory B Cells are Major Targets for Effective Immunotherapy in Relapsing Multiple Sclerosis.

Baker D, Marta M, Pryce G, Giovannoni G, Schmierer K.

EBioMedicine. 2017 Feb;16:41-50. doi: 10.1016/j.ebiom.2017.01.042. Epub 2017 Jan 31. Review.

12.

The effect of glatiramer acetate therapy on functional properties of B cells from patients with relapsing-remitting multiple sclerosis.

Ireland SJ, Guzman AA, O'Brien DE, Hughes S, Greenberg B, Flores A, Graves D, Remington G, Frohman EM, Davis LS, Monson NL.

JAMA Neurol. 2014 Nov;71(11):1421-8. doi: 10.1001/jamaneurol.2014.1472.

13.

Dimethyl Fumarate Treatment Mediates an Anti-Inflammatory Shift in B Cell Subsets of Patients with Multiple Sclerosis.

Li R, Rezk A, Ghadiri M, Luessi F, Zipp F, Li H, Giacomini PS, Antel J, Bar-Or A.

J Immunol. 2017 Jan 15;198(2):691-698. doi: 10.4049/jimmunol.1601649. Epub 2016 Dec 14.

14.

Alemtuzumab for the treatment of relapsing-remitting multiple sclerosis.

Hersh CM, Cohen JA.

Immunotherapy. 2014;6(3):249-59. doi: 10.2217/imt.14.7. Review.

PMID:
24762071
15.

Compositional changes of B and T cell subtypes during fingolimod treatment in multiple sclerosis patients: a 12-month follow-up study.

Claes N, Dhaeze T, Fraussen J, Broux B, Van Wijmeersch B, Stinissen P, Hupperts R, Hellings N, Somers V.

PLoS One. 2014 Oct 31;9(10):e111115. doi: 10.1371/journal.pone.0111115. eCollection 2014.

16.

Regulatory and effector B cell cytokine production in patients with relapsing granulomatosis with polyangiitis.

Land J, Abdulahad WH, Sanders JS, Stegeman CA, Heeringa P, Rutgers A.

Arthritis Res Ther. 2016 Apr 4;18:84. doi: 10.1186/s13075-016-0978-1.

17.

IFN-β treatment requires B cells for efficacy in neuroautoimmunity.

Schubert RD, Hu Y, Kumar G, Szeto S, Abraham P, Winderl J, Guthridge JM, Pardo G, Dunn J, Steinman L, Axtell RC.

J Immunol. 2015 Mar 1;194(5):2110-6. doi: 10.4049/jimmunol.1402029. Epub 2015 Feb 2.

18.

Longitudinal assessment of immuno-metabolic parameters in multiple sclerosis patients during treatment with glatiramer acetate.

Carrieri PB, Carbone F, Perna F, Bruzzese D, La Rocca C, Galgani M, Montella S, Petracca M, Florio C, Maniscalco GT, Spitaleri DL, Iuliano G, Tedeschi G, Della Corte M, Bonavita S, Matarese G.

Metabolism. 2015 Sep;64(9):1112-21. doi: 10.1016/j.metabol.2015.05.001. Epub 2015 May 8.

PMID:
25986733
19.
20.

CRYAB modulates the activation of CD4+ T cells from relapsing-remitting multiple sclerosis patients.

Quach QL, Metz LM, Thomas JC, Rothbard JB, Steinman L, Ousman SS.

Mult Scler. 2013 Dec;19(14):1867-77. doi: 10.1177/1352458513489853. Epub 2013 Jun 4.

PMID:
23736536

Supplemental Content

Support Center